NEW YORK, NY / ACCESS Newswire / March 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...
Biohaven (NYSE:BHVN – Free Report) had its price objective lowered by Morgan Stanley from $69.00 to $63.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an ...
Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company's potential treatment for a rare disease. The FDA's Decision on BHVN's Drug Candidate The FDA agreed to review BHVN's ...
$BHVN insiders have traded $BHVN stock on the open market 8 times in the past 6 months. Of those trades, 8 have been purchases and 0 have been sales. Here’s a ...
Shares of BHVN opened at $29.87 on Wednesday. Biohaven has a 1-year low of $26.80 and a 1-year high of $62.21. The stock has a market cap of $3.02 billion, a PE ratio of -3.19 and a beta of 1.27 ...
Following Pfizer’s acquisition, Biohaven’s valuation skyrocketed under Vlad Coric. Find out why BHVN stock’s growth potential ...
Investors in Biohaven Ltd (Symbol: BHVN) saw new options become available this week, for the October 17th expiration. One of the key data points that goes into the price an option buyer is willing ...
Explore Biohaven stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for BHVN. Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results